Skip to main content
Premium Trial:

Request an Annual Quote

NIH Grants New England Biolabs $640K for Epigenetic Tools Development

NEW YORK (GenomeWeb News) – New England Biolabs announced Thursday that it has received a $640,000 Phase II Small Business Innovation grant from the National Institutes of Health to expand its research into development of enzymatic tools for epigenetic analysis.

The Ipswich, Mass.-based company said it has focused on using restriction enzymes in epigenetic studies for years, and research into methylation-dependent and methylation-sensitive restriction enzymes has resulted in new tools for identifying such DNA modifications. The grant announced today will enable additional research into this area, resulting in "a deeper understanding of epigenetic marks in the mammalian genome."

In 2010 New England Biolabs received an SBIR grant for $1.2 million for research into and the development of enzymatic reagents for epigenetics. It said today that it has received more than $1.1 million in SBIR funds since 2009.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.